13 results about "Attention deficit disorder" patented technology

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This application relates to a method, apparatus, and device for screening the risk of reading and attention deficit disorder in children. The method includes acquiring multi-channel raw brain blood oxygenation signals under task-induced conditions using a specific layout fNIRS array integrated into a wearable headband, based on a rapid naming cognitive paradigm. Based on the raw brain blood oxygenation signals, a fusion feature vector representing the reading and attention networks is generated by calculating temporal waveform features and frontotemporal functional connectivity strength. The multi-dimensional fusion feature vector is then processed and analyzed using a Transformer classification model to generate classification results indicating the risk level of reading disorders and comorbid ADHD. This application achieves portable and rapid brain function signal acquisition by integrating a targeted fNIRS array with a standardized cognitive paradigm. By fusing temporal dynamics and brain network connectivity features, a multi-dimensional neural representation is constructed. Finally, a lightweight Transformer model is used to output the risk level of reading disorders and comorbid ADHD end-to-end, achieving high-precision automated assisted screening.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The present technology relates to sensory apparatuses that are useful for individuals who need assistance with neurodevelopmental conditions such as autism spectrum disorder (ASD), sensory processing disorder (SPD), attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Such apparatuses can include a top cover connected to or integral with a top base plate, and a bottom cover connected to or integral with a bottom base plate, about which projections or wings having different visual or tactile properties, such as different textures, are rotatably attached. The present technology is also directed to systems and methods for the management of a neurodevelopmental condition.

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

A system for treating an attention deficit disorder or for improving attention in a user. The system including a wearable device including a plurality of electrodes configured to be disposed over a region of a prefrontal cortex of a patient when the wearable device is worn by the patient a controller operatively coupled to the plurality of electrodes and configured to cause the plurality of electrodes to deliver a treatment session, the treatment session including delivery of transcranial random noise stimulation (tRNS) to the region of the prefrontal cortex with an current amplitude in a range of about 0.5 milliamps (mA) to about 2 mA for a period of time.

The present invention relates to the use of HIP / PAP proteins or derivatives thereof in therapy and prophylaxis, in particular to the use of said HIP / PAP proteins or derivatives thereof in the treatment of cognitive disorders associated with one or more anxiety disorders in an individual in need thereof, and for improving cognitive function in an individual affected by a nervous system condition associated with one or more anxiety disorders, or for alleviating cognitive deficits in a subject suffering from a condition selected from the group consisting of obsessive-compulsive disorder, attention deficit disorder, Lewy body dementia, early onset dementia, epilepsy-related cognitive dysfunction, frontotemporal dementia, posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar affective disorder, substance abuse, attention deficit disorder, etc. A psychiatric disorder and an SARS-CoV-2 infection; and for the prevention and / or treatment of diet-induced cognitive and anxiety deficits in an individual in need thereof, in particular for the prevention and / or treatment of cognitive and anxiety deficits caused by high fat diet.

Subject matter of the present invention is supplementation for treatment and / or prophylaxis of a neurodevelopmental or psychiatric disorder in a human patient in need thereof, wherein said patient suffers from a neurodevelopmental or psychiatric disorder selected from the group comprising attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), impulse control disorder and learning disorder and wherein said iron supplementation is selected from the group comprising an intravenous iron supplementation, parenteral iron supplementation, oral iron supplementation, intraaerterial iron supplementation or intramuscular iron supplementation, preferably an intravenous iron supplementation.

There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.